Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Elevation Oncology, Inc.

Get SEC filing alerts via email and in your feed for Elevation Oncology, Inc.

ELEV

Elevation Oncology, Inc.

About Elevation Oncology, Inc.

Elevation Oncology, Inc. is an innovative oncology company specializing in the discovery and development of targeted cancer therapies, primarily antibody-drug conjugates (ADCs). Its pipeline includes EO-3021, targeting Claudin 18.2 in gastric and other cancers, and EO-1022, targeting HER3 in solid tumors. The company focuses on addressing unmet medical needs through precision medicine, leveraging proprietary ADC technology, strategic collaborations, and a global development and commercialization approach.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Elevation Oncology, Inc.

1
1
Elevation Oncology, Inc. Elevation Oncology Reports $44.5 Million Net Loss for 2024, Highlights EO-3021 Clinical Trial Success

Via official filing (AI summary) | over 1 year ago | 0 comments